UniQure pushes back on FDA's criticism of Huntington’s therapy; shares up

uniQure

06/03/2026 16:44

** U.S.-listed shares of Dutch drugmaker UniQure UQ1.F, QURE.O rise 12% to $11.93

** UniQure, late on Thursday, pushed back against the FDA's comments and said its Huntington’s gene therapy data remains strong

** Co is developing a gene therapy, AMT-130, for Huntington’s disease, a rare condition that affects motor function

** On Thursday, a senior FDA official, in a conference call with media, called UniQure's drug a "failed product "

** UniQure, in a statement, called the remarks "highly irregular, unprecedented, and are incomplete or entirely incorrect"

** "We do not believe they reflect a fair and faithful reading of the documents we have submitted or those we have received from the agency," it added

** UniQure rose 35.5% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))